Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
MELBOURNE, Australia and OXFORD, United Kingdom Nov. 20, 2024 /PRNewswire/ -- Pathios Therapeutics ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced dosing of the first patient in the initial module of a Phase 1/2 clinical trial evaluating PTT-4256, the company's investigational first-in-class GPR65 inhibitor. PTT-4256 is an internally discovered, oral, highly potent, and selective small molecule inhibitor of the pH-sensing GPR65. The RAISIC-1 trial (Relief of Acidic Immune Suppression in Cancer) is a modular multi-part, multi-arm open-label study being conducted in Australia . The study's first module is designed to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of PTT-4256 monotherapy in patients with a range of advanced solid tumours. Subsequent modules will explore the potential of PTT-4256 in specific tumour types, including in combination with different standards of care. "The tran
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Is Bristol Myers Squibb Stock a Buy? [Yahoo! Finance]Yahoo! Finance
- Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks [Yahoo! Finance]Yahoo! Finance
- Effervescent Tablet Market to Grow by USD 4.80 Billion (2024-2028) as AI Impacts Market Trends, Rising Adoption Among Aging Population Boosts Revenue - Technavio [Yahoo! Finance]Yahoo! Finance
- Transplant Therapeutics Consortium Receives FDA Acceptance of the Qualification Plan for iBox Scoring System [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 10/31/24 - Beat
BMY
Sec Filings
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- BMY's page on the SEC website